<form id="lwufo"><acronym id="lwufo"></acronym></form>
          Log in
          E-mail
          Password
          Remember
          Forgot password ?
          Become a member for free
          Sign up
          Sign up
          New member
          Sign up for FREE
          New customer
          Discover our services
          Settings
          Settings
          Dynamic quotes 
          OFFON

          MarketScreener Homepage  >  Equities  >  Nasdaq  >  Forty Seven, Inc.    

          FORTY SEVEN, INC.

           SummaryNewsRatingsCompany 
          Company
          Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company鈥檚 lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company鈥檚 another product FSI-189,... 
          More about the company
          Notations Surperformance© of Forty Seven, Inc.
          Trading Rating : Investor Rating : -
          More Ratings
          All news about FORTY SEVEN, INC.
          04/07FORTY SEVEN, INC. : Completion of Acquisition or Disposition of Assets, Notice o..
          AQ
          03/20FORTY SEVEN : Management's Discussion and Analysis of Financial Condition and Re..
          AQ
          03/20Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results..
          GL
          03/17FORTY SEVEN ALERT : Bragar Eagel & Squire, P.C. Investigates Sale of FTSV and En..
          PR
          03/11Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fa..
          GL
          03/06Monteverde & Associates PC Announces an Investigation of Forty Seven, Inc. - ..
          PR
          03/03Thermo Fisher agrees to buy genetic tester Qiagen in $11.5 billion deal
          RE
          03/02Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline
          RE
          03/02FORTY SEVEN : Gilead to Acquire Forty Seven for $4.9 Billion
          BU
          03/02FORTY SEVEN, INC. : Entry into a Material Definitive Agreement, Other Events, Fi..
          AQ
          03/02GILEAD SCIENCES : buying Forty Seven for $4.9 billion
          AQ
          02/28Beyond Meat, Dell fall; 3M, Forty Seven rise
          AQ
          02/25Forty Seven to Present at Upcoming Investor Conferences in March
          GL
          02/06Forty Seven to Present at Upcoming Investor Conferences in February
          GL
          01/10FORTY SEVEN, INC. : Entry into a Material Definitive Agreement, Financial Statem..
          AQ
          More news
          News in other languages on FORTY SEVEN, INC.
          03/02WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
          02/28EN DIRECT DES MARCHES : Safran, Veolia, Saint-Gobain, Lagardère, Korian, GTT,..
          02/28STOCK MARKET PARIS : Vent de panique sur les marchés financiers
          More news
          Managers
          NameTitle
          Andrew D. Dickinson President, Treasurer & Director
          Kyle C. Elrod Senior Vice President-Planning & Operations
          Chris H. Takimoto Chief Medical Officer
          Brett A. Pletcher Secretary & Director
          Christina Carlson Director
          Sector and Competitors
          1st jan.Capitalization (M$)
          FORTY SEVEN, INC.142.60%4 599
          GILEAD SCIENCES, INC.-7.65%75 173
          REGENERON PHARMACEUTICALS55.14%61 638
          VERTEX PHARMACEUTICALS-3.09%53 956
          WUXI APPTEC CO., LTD.64.97%37 810
          BEIGENE, LTD.81.91%27 304
          官方真人棋牌游戏平台